Where does Rigel Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Rigel Pharmaceuticals, Inc. ranks #2,083 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Rigel Pharmaceuticals, Inc. hold?

Rigel Pharmaceuticals, Inc. holds 190 US utility patents granted between 2015 and 2025, spanning 18 technology areas.

What is Rigel Pharmaceuticals, Inc.'s Innovation Score?

Rigel Pharmaceuticals, Inc. has an Innovation Score of 48.0 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Rigel Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Rigel Pharmaceuticals, Inc.'s recent grant velocity is -43% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Rigel Pharmaceuticals, Inc.'s patents?

Rigel Pharmaceuticals, Inc.'s patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Rigel Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Rigel Pharmaceuticals, Inc.

Q: What technology areas does Rigel Pharmaceuticals, Inc. focus on?

Rigel Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 176 patents. Grants appear in 18 CPC subclasses total.

USPTO PatentsView assignee record - 190 granted patents across 18 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Rigel ranks #2,083 of 49,997 tracked US assignees by granted-patent volume, with 190 patents across 18 technology areas.

#2,083
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.0/100): 17.9
avg claims per patent: -43%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2083 · US Corporation #2,083 · 190 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 190 grants
TOP-DECILE #2,083/49,997
PHOTO-FINISH Elekta
CPC-FOCUS A61P · 18 areas
INNOV-PAR 48.0/100
CLAIMS-RICH 17.9 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -43% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Elekta Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Dwango · near

48
IHC Holland IE B V · near

48
Longyear TM · near

48
Pcms Holdings · near

48
Rigel Pharmaceuticals · this assignee

48
3D Lighting… · lowest

7

What this shows Rigel's Innovation Score is 48.0/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Rigel's grants concentrate

Rigel Pharmaceuticals, Inc. is a focused PatentsView assignee: 18 CPC subclasses with 92.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (35 grants) versus a trough of 7 in 2023. By volume, Rigel sits between Elekta Limited and Allscripts Software, LLC.

Rigel's three-year grant acceleration

From 2019–2021 to 2022–2024, Rigel Pharmaceuticals, Inc. moved from 54 to 33 grants (0.61x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,424. See the growth leaderboard.

Elekta

190
National Central…

190
Ocado Innovation

190
Richwave Technolo…

190
Shionogi &

190
Smith & Nephew Or…

190
Volvo Lastvagnar…

190
Rigel Pharmaceuti… ◀

190
Allscripts Softwa…

189

What this shows Rigel holds 190 patents at rank #2,083, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Rigel

By rank, the assignees closest to #2,083 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Rigel's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Rigel, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (48 here).

Dwango Co., Ltd. 48 Pcms Holdings, Inc. 48 IHC Holland IE B.V. 48 Longyear TM, Inc. 48

Similar claim depth

Nearest assignees by average claims per patent (17.9 here).

TDK Electronics AG 17.9 avg University of Massachusetts 17.9 avg Biocatch Ltd. 17.9 avg CommScope, Inc. of North Carolina 17.9 avg

Rigel's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Rigel Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	35	18.4%
2016	22	11.6%
2017	25	13.2%
2018	15	7.9%
2019	20	10.5%
2020	19	10.0%
2021	15	7.9%
2022	19	10.0%
2023	7	3.7%
2024	7	3.7%
2025partial year	6	3.2%

Which technologies does Rigel Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 176

C07D - Heterocyclic Compounds 168

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 107

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 52

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 12

C07K - Peptides 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 8

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 6

Y02A - Technologies FOR Adaptation TO Climate Change 6

C12Y - Enzymes 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C07C - Acyclic OR Carbocyclic Compounds 4

C07J - Steroids 3

Y10T - Technical Subjects Covered BY Former US Classification 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 15 of 18 technology areas

Where it ranks

Overall rank by patents

#2,083

of 49,997 tracked assignees

Innovation Score

48.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Rigel Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Rigel Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.6% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,083 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Rigel Pharmaceuticals, Inc. against Elekta Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.